Al-Ola Abdallah, Board Member at Kansas Society of Clinical Oncology, Associate Professor of Medicine, Assistant Professor at University of Kansas Medical Center, shared a post on LinkedIn:
“At the 2026 National ICE-T Conference in Charlotte, Prerna Mewawalla, discussed the potential role of the investigational FcRH5xCD3 bispecific cevostamab in helping fill critical gaps in the multiple myeloma treatment landscape.”
More posts featuring Al-Ola Abdallah.